Anaplastic thyroid carcinoma (ATC) is a rare and aggressive endocrine tumor with highly undifferentiated morphology. It has been suggested that cancer stem cells (CSCs) might play a central role in ATC. The objectives of this study were (i) to characterize CSCs from ex vivo ATC specimens by investigating the expression of several pluripotent stem cell markers, and (ii) to evaluate in vitro drug resistance modifications after specific CSC transcription factor switch-off.
Methods:
In ex vivo experiments, eight formalin-fixed, paraffin-embedded ATC specimens were analyzed by reverse-transcription and real-time quantitative PCR and immunohistochemistry. In in vitro experiments using ATC SW1736 cells, the expression levels of OCT-4, NANOG, and ABCG2 and the sensitivity to either cisplatin or doxorubicin were evaluated after silencing.
Results:
OCT-4, KLF4, and SOX2 transcription factors and C-KIT and THY-1 stem surface antigens showed variable up-regulation in all ATC cases. The SW1736 cell line was characterized by a high percentage of stem population (10.4±2.1% of cells were aldehyde dehydrogenase positive) and high expression of several CSC markers (SOX2, OCT4, NANOG, C-MYC, and SSEA4). SOX2 silencing down-regulated OCT-4, NANOG, and ABCG2. SOX2 silencing sensitized SW1736 cells, causing a significant cell death increase (1.8-fold) in comparison to control cells with 10 μM cisplatin (93.9±3.4% vs. 52.6±9.4%, p<0.01) and 2.7 fold with 0.5 μM doxorubicin (45.8±9.9% vs. 17.1±3.4% p<0.01). ABCG2 silencing caused increased cell death with both cisplatin (74.9±1.4%) and doxorubicin treatment (74.1±0.1%) vs. no-target–treated cells (respectively, 45.8±1.0% and 48.6±1.0%, p<0.001).
Conclusions
: The characterization of CSCs in ATC through the analysis of multiple pluripotent stem cell markers might be useful in identifying cells with a stem-like phenotype capable of resisting conventional chemotherapy. In addition, our data demonstrate that SOX2 switch-off through ABCG2 transporter down-regulation has a major role in overcoming CSC chemotherapy resistance.
Get full access to this article
View all access options for this article.
References
1.
GharibH, PapiniE, PaschkeR. 2008. Thyroid nodules: a review of current guidelines, practices, and prospects. Eur J Endocrinol, 159:493–505.
2.
ThomasT, NowkaK, LanL, DerwahlM. 2006. Expression of endoderm stem cell markers: evidence for the presence of adult stem cells in human thyroid. Thyroid, 16:537–544.
3.
ThomasD, FriedmanS, LinRY. 2008. Thyroid stem cells: lessons from normal development and thyroid cancer. Endocr Relat Cancer, 15:51–58.
Al-HajjM, WichaMS, Benito-HernandezA, MorrisonSJ, ClarkeMF. 2003. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A, 100:3983–3988.
6.
SinghSK, ClarkeID, TerasakiM, BonnVE, HawkinsC, SquireJ, DirksPB. 2003. Identification of a cancer stem cell in human brain tumours. Cancer Res, 63:5821–5828.
7.
O'BrienCA, PollettA, GallingerS, DickJE. 2006. A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature, 445:106–110.
TakanoT, AminoN. 2005. Fetal cell carcinogenesis: a new hypothesis for better understanding of thyroid carcinoma. Thyroid, 15:432–438.
10.
SchweppeRE, KlopperJP, KorchC, PugazhenthiU, BenezraM, KnaufJA, FaginJA, MarlowLA, CoplandJA, SmallridgeRC, HaugenBR. 2008. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab, 93:4331–4341.
11.
AlisonMR, LinWR, LimSM, NicholsonLJ. 2012. Cancer stem cells: in the line of fire. Cancer Treat Rev, 38:589–598.
12.
PellegritiG, De VathaireF, ScolloC, AttardM, GiordanoC, ArenaS, DardanoniG, FrascaF, MalandrinoP, VermiglioF, PreviteraDM, D'AzzòG, TrimarchiF, VigneriR. 2009. Papillary thyroid cancer incidence in the volcanic area of Sicily. J Natl Cancer Inst, 101:1575–1583.
13.
World Health Organization. 2004. Classification of Tumours. athology and Genetics of Tumours of Endocrine Organs, First. IARC Press: Lyon.
14.
ZitoG, RichiusaP, BommaritoA, CarissimiE, RussoL, CoppolaA, ZerilliM, RodolicoV, CriscimannaA, AmatoM, PizzolantiG, GalluzzoA, GiordanoC. 2008. In vitro identification and characterization of CD133pos cancer stem-like cell in anaplastic carcinoma cell lines. PLoS One, 3,10:e3544.
15.
ReyaT, MorrisonSJ, ClarkeMF, WeissmanIL. 2001. Stem cells, cancer, and cancer stem cells. Nature, 414:105–111.
16.
TakahashiK, TanabeK, OhnukiM, NaritaM, IchisakaT, TomodaK, YamanakaS. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131:861–872.
PatnaikMM, TefferiA, PardananiA. 2007. Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders. Curr Cancer Drug Targets, 7:492–503.
19.
RegeTA, HagoodJS. 2006. Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J, 20:1045–1054.
20.
TokuyamaS, SaitoS, TakahashiT, OhyamaC, ItoA, KantoS, SatohM, HoshiS, EndohM, AraiY. 2003. Immunostaining of stage-specific embryonic antigen-4 in intratubular germ cell neoplasia unclassified and in testicular germ-cell tumours. Oncol Rep, 10:1097–1104.
21.
AlonsoMM, Diez-ValleR, ManterolaL, RubioA, LiuD, Cortes-SantiagoN, UrquizaL, JauregiP, de MunainAL, SampronN, AramburuA, Tejada-SolísS, VicenteC, OderoMD, BandrésE, García-FoncillasJ, IdoateMA, LangFF, FueyoJ, Gomez-ManzanoC. 2011. Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One, 6:e26740
22.
GangemiRM, GrifferoF, MarubbiD, PereraM, CapraMC, MalatestaP, RavettiGL, ZonaGL, DagaA, CorteG. 2009. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells, 27:40–48.
23.
GüreAO, StockertE, ScanlanMJ, KeresztesRS, JägerD, AltorkiNK, OldLJ, ChenYT. 2000. Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc Natl Acad Sci U S A, 97:4188–4203.
24.
Rodriguez-PinillaSM, SarrioD, Moreno-BuenoG, Rodriguez-GilY, MartinezMA, HernandezL, HardissonD, Reis-FilhoJS, PalaciosJ. 2007. Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol, 20:474–481.
25.
MasuiS, NakatakeY, ToyookaY, ShimosatoD, YagiR, TakahashiK, OkochiH, OkudaA, MatobaR, SharovAA, KoMS, NiwaH. 2007. Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol, 9:625–635.
26.
GuGY, YuanJL, WillsM, KasperS. 2007. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res, 67:4807–4815.
27.
ChiouSH, YuCC, HuangCY, LinSC, LiuCJ, TsaiTH, ChouSH, ChienCS, KuHH, LoJF. 2008. Positive correlations of Oct4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res, 14:4085–4095.
28.
RoddaDJ, ChewJL, LimLH, LohYH, WangB, NgHH, RobsonP. 2005. Transcriptional regulation of nanog by OCT4 and SOX2. J Biol Chem, 280:24731–24737.
29.
XiangR, LiaoD, ChengT, ZhouH, ShiQ, ChuangTS, MarkowitzD, ReisfeldRA, LuoY. 2011. Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br J Cancer, 104:1931
30.
CeckovaM, VackovaZ, RadilovaH, LibraA, BuncekM, StaudF. 2008. Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP. Toxicol In Vitro, 22:1846–1852.
31.
CalcagnoAM, FostelJM, ToKK, SalcidoCD, MartinSE, ChewningKJ, WuCP, VarticovskiL, BatesSE, CaplenNJ, AmbudkarSV. 2008. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. Br J Cancer, 98:1515–1524.
32.
ZhengX, CuiD, XuS, BrabantG, DerwahlM. 2010. Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: characterization of resistant cells. Int J Oncol, 37:307–315.
33.
SinghS, TrevinoJG, Bora-SinghalN, CoppolaD, HauraE, AltiokS, ChellappanSP. 2012. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer, 11:73.
34.
LinF, LinP, ZhaoD, ChenY, XiaoL, QinW, LiD, ChenH, ZhaoB, ZouH, ZhengX, YuX. 2012. Sox2 targets cyclinE, p27 and survivin to regulate androgen-independent human prostate cancer cell proliferation and apoptosis. Cell Prolif, 45:207–216.
35.
PrasmickaiteL, EngesæterBØ, SkrboN, HellenesT, KristianA, NinaK, OliverNK, SuoZ, MælandsmoGM. 2010. Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma. PLoS One, 5:e10731.
36.
ChangB, LiuG, XueF, RosenDG, XiaoL, WangX, JinsongLiu J. 2009. ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol, 22:817–823.
37.
SilvaIA, BaiS, McLeanK, YangK, GriffithK, ThomasD, GinestierC, JohnstonC, KueckA, ReynoldsRK, WichaMS, BuckanovichRJ. 2011. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res, 71:3991–4001.
38.
KryczekI, LiuS, RohM, VatanL, SzeligaW, WeiS, BanerjeeM, MaoY, KotarskiJ, WichaMS, LiuR, ZouW. 2012. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer, 130:29–39.
39.
GinestierC, HurMH, Charafe-JauffretE, MonvilleF, DutcherJ, BrownM, JacquemierJ, ViensP, KleerCG, LiuS, SchottA, HayesD, BirnbaumD, WichaMS, DontuG. 2007. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 1:555–567.
40.
JelskiW, ChrostekL, SzmitkowskiM. 2007. The activity of class I, II, III, IV of alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase in pancreatic cancer. Pancreas, 35:142–146.
41.
PearceDJ, TaussigD, SimpsonC, AllenK, RohatinerAZ, ListerTA, BonnetD. 2005. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells, 23:752–760.
42.
UcarD, CogleCR, ZucaliJR, OstmarkB, ScottEW, ZoriR, GrayBA, MorebJS. 2009. Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem Biol Interact, 178:48–55.
43.
TaubertI, SaffrichR, Zepeda-MorenoA, HellwigI, EcksteinV, BrucknerT, HoAD, WuchterP. 2011. Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor. Cytotherapy, 13:459–466.
